Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer

Overview of attention for article published in Frontiers in oncology, November 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 8 X users

reddit: 1 Redditor

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 25 Mendeley

Summary X Reddit Dimensions citations

So far, Altmetric has seen 9 X posts from 8 X users, with an upper bound of 106,239 followers.

New research: Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer: Introduction: Multicenter, phase I study of… https://t.c

26 Dec 2019

Reply Repost Favourite

RT @StephenVLiu: #OncoAlert Trial led by Jonathan Goldman and Karen Kelly of 1L carbo, nab-pac and nivolumab concurrently or phased/delayed…

27 Nov 2019

Reply Repost Favourite

RT @StephenVLiu: #OncoAlert Trial led by Jonathan Goldman and Karen Kelly of 1L carbo, nab-pac and nivolumab concurrently or phased/delayed…

27 Nov 2019

Reply Repost Favourite

RT @StephenVLiu: #OncoAlert Trial led by Jonathan Goldman and Karen Kelly of 1L carbo, nab-pac and nivolumab concurrently or phased/delayed…

27 Nov 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.